Vesalius has provided $4.7m to Forendo Pharma, whose existing shareholders also include Karolinska Development, Novartis, Novo and Merck Group.
Forendo Pharma, a Finland-based gynaecological therapy based on research from University of Turku, secured €4m ($4.7m) in funding on Wednesday from Vesalius Biocapital III Partners, a growth-stage vehicle managed by VC firm Vesalius Biocapital Partners.
Forendo Pharma focuses on the development of therapies for disorders affecting the organs in the female pelvic and abdominal regions.
The spinout’s lead development candidate, For 6219, targets a long-term condition called endometriosis where internal womb tissue has proliferated into external areas such as the…
